OpportunityAnalyzer: Small Cell Lung Cancer (SCLC) - Opportunity Analysis and Forecasts to 2024: MarketResearchReports.biz
Initially considered a curable disease due to substantial sensitivity to first-line chemotherapies, small cell lung cancer (SCLC) remains a fatal disease with poor outcomes due to high relapse rates, with the majority of patients surviving one year or less after diagnosis. Unlike non-small cell lung cancer (NSCLC), in which major advances in treatment have been made following the approval of several targeted therapies, the field of SCLC has seen little advancement for several decades.
View full press release